跳至主要内容
临床试验/NCT04743622
NCT04743622已完成4 期

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients

CHA University1 个研究点 分布在 1 个国家目标入组 57 人开始时间: 2019年4月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
57
试验地点
1
主要终点
Corneal staining test

研究概览

简要总结

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Study

详细描述

Not provided

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • IOP >/= 15mmHg and < 40 mmHg in each eye using Goldmann applanation tonometry at visit 2
  • Written consent voluntarily to participate in this clinical trial

排除标准

  • Patients with closed-angle, congenital glaucoma or secondary glaucoma caused by steroid drugs, etc.
  • best-corrected visual acuity 20/80 or less
  • Patients who have ongoing medical history of ocular inflammation
  • central corneal thickness is not in between 470um and 591um.
  • Patients who have received lacrimal duct procedure within the last 3 months or who have plans to have it.
  • pregnant or nursing women

研究组 & 干预措施

Monoprost (preservative-free latanoprost eye drop)

Experimental

latanoprost : 1 drop once a day for 12 weeks to target eyes

干预措施: Monoprost (Drug)

Xalatan (preserved latanoprost eye drop)

Active Comparator

latanoprost : 1 drop once a day for 12 weeks to target eyes

干预措施: Xalatan (Drug)

结局指标

主要结局

Corneal staining test

时间窗: (12-week-point)

The degree of staining of the cornea after blue fluorescein staining under the light of cobalt blue using a yellow filter was evaluated according to the Oxford grading system (0 to 5, the higher the worse)

Conjunctival staining test

时间窗: (12-week-point)

The conjunctiva was divided into 6 areas and evaluated after the same staining method according to the Oxford grading system (0 to 3, the higher the worse)

Ocular surface disease index (OSDI)

时间窗: (12-week-point)

The ocular surface was assessed using OSDI scoring questionnaire (0 to 100, the higher the worse)

Compliance check

时间窗: (12-week-point)

Compliance of the drug administration has been check through the subject's self description (0 to 100, the higher the better)

次要结局

  • Conjunctival staining test((4-week-point))
  • Corneal staining test((4-week-point))
  • IOP (intraocular pressure)((4- / 12-week-point))
  • Tear break up time (TBUT)((4- / 12-week-point))
  • Limbal and bulbar hyperemia((4- / 12-week-point))
  • Ocular surface disease indext (OSDI)((4-week-point))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验